RU2016126423A - Композиции и способы лечения внутримозгового кровоизлияния - Google Patents

Композиции и способы лечения внутримозгового кровоизлияния Download PDF

Info

Publication number
RU2016126423A
RU2016126423A RU2016126423A RU2016126423A RU2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A
Authority
RU
Russia
Prior art keywords
less
ich
mmhg
leu
seq
Prior art date
Application number
RU2016126423A
Other languages
English (en)
Russian (ru)
Other versions
RU2016126423A3 (https=
Inventor
Стивен АРКИН
Хоаким ФРУБИС
Маркус И. КАРР
Санита ХЕТТ
Реема ДЖАСУДЖА
Дебра Д. ПИТТМАН
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2016126423A3 publication Critical patent/RU2016126423A3/ru
Publication of RU2016126423A publication Critical patent/RU2016126423A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016126423A 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния RU2016126423A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
RU2016126423A3 RU2016126423A3 (https=) 2018-03-01
RU2016126423A true RU2016126423A (ru) 2018-03-01

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016126423A RU2016126423A (ru) 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния

Country Status (18)

Country Link
US (2) US20160375109A1 (https=)
EP (1) EP3096779B1 (https=)
JP (1) JP6624787B2 (https=)
KR (3) KR20210008177A (https=)
CN (2) CN112156176A (https=)
AU (1) AU2015208819B2 (https=)
BR (1) BR112016014617A2 (https=)
CA (1) CA2937418A1 (https=)
DK (1) DK3096779T3 (https=)
ES (1) ES2772802T3 (https=)
HU (1) HUE047588T4 (https=)
IL (1) IL246637A0 (https=)
MX (1) MX375355B (https=)
PL (1) PL3096779T3 (https=)
PT (1) PT3096779T (https=)
RU (1) RU2016126423A (https=)
SI (1) SI3096779T1 (https=)
WO (1) WO2015110939A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016406D1 (de) * 2004-06-21 2009-10-15 Novo Nordisk Healthcare Ag Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ödemerzeugung nach intrazerebraler hämorrhagie (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
EP2950813B1 (en) * 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
EP3096779A1 (en) 2016-11-30
PT3096779T (pt) 2020-02-21
JP2015147764A (ja) 2015-08-20
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX2016009665A (es) 2016-11-14
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
AU2015208819A1 (en) 2016-06-30
IL246637A0 (en) 2016-08-31
CA2937418A1 (en) 2015-07-30
RU2016126423A3 (https=) 2018-03-01
US20190231856A1 (en) 2019-08-01
DK3096779T3 (da) 2020-02-24
JP6624787B2 (ja) 2019-12-25
ES2772802T3 (es) 2020-07-08
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
US20160375109A1 (en) 2016-12-29
CN112156176A (zh) 2021-01-01
MX375355B (es) 2025-03-04
KR20180014221A (ko) 2018-02-07
CN105934250A (zh) 2016-09-07
SI3096779T1 (sl) 2020-03-31
BR112016014617A2 (pt) 2017-09-19
HUE047588T4 (hu) 2020-06-29

Similar Documents

Publication Publication Date Title
US20180099027A1 (en) Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
Cerri et al. Chemokines as new inflammatory players in the pathogenesis of epilepsy
RU2010140886A (ru) Применение дефенсинов при туберкулезе
RU2707191C2 (ru) Нейродегенеративные расстройства
Wang et al. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice
Akyuz et al. Effect of early bilateral decompressive craniectomy on outcome for severe traumatic brain injury.
EP3463575B1 (en) Methods and compositions for modulating lymphatic vessels in the central nervous system
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
KR20150018555A (ko) 뇌졸중 후 신경발생을 촉진시키는 세마포린-４d 결합 분자의 용도
RU2016126423A (ru) Композиции и способы лечения внутримозгового кровоизлияния
JP2020502140A (ja) 糖尿病を治療するための新しい方法
Faraji et al. Harnessing BDNF signaling to promote resilience in aging
Hou et al. Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis
ES2965087T3 (es) Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
Tang et al. TREM2 alleviates long-term cognitive dysfunction after subarachnoid hemorrhage in mice by attenuating hippocampal neuroinflammation via PI3K/Akt signaling pathway
WO2017180841A1 (en) Treatment of cerebral cavernous malformations
JP2015147764A5 (https=)
US20130165376A1 (en) Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation
US20190002517A1 (en) Neuropeptide y-derived peptides
MX2021003123A (es) Isomeros rotomericos de 4-alquil-5-heteroaril-3h-1,2-ditiol-3-tion as.
WO2015121428A1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
WO2015136255A1 (en) Combined inhibition of caspase-2 and caspase-6 in neuroprotection and axon regeneration
Maghsoudi et al. Intraperitoneal Carbamylated erythropoietin improves memory and hippocampal apoptosis in beta-amyloid rat model of Alzheimer’, s disease through stimulating autophagy and inhibiting necroptosis
Lu et al. The prognostic utility of no evidence of disease activity (neda)
Ostroukhova et al. Migraine and orexin

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190121